A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Rao, Soumya Alige Mahabala ^a   Srinivasan, Sujaya ^a   Patric, Irene Rosita Pia ^a   Hegde, Alangar Sathyaranjandas ^b   Chandramouli, Bangalore Ashwathnarayanara ^c   Arimappamagan, Arivazhagan ^c   Santosh, Vani ^c   Kondaiah, Paturu ^a   Sathyanarayana Rao, Manchanahalli R ^d   Somasundaram, Kumaravel ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b SRI SATHYA SAI INSTITUTE OF HIGHER MEDICAL SCIENCES   (India)

^c NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^d JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GRADING; CLASSIFIER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FOCAL ADHESION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ASTROCYTOMA; CLUSTER ANALYSIS; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GLIOBLASTOMA; HUMANS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84895929399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085200     Document Type: Article

References (49)

1. CBTRUS (2008) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008, Central Brain Tumor Registry of the United States, 2000-2004. Available: http://www.cbtrus. org/2012-NPCR-SEER/CBTRUS-Report- 2004-2008-3-23-2012.pdf. Accessed 2012 Oct 10.
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710. (Pubitemid 350070717)
3. Reardon DA, Wen PY (2006) Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11: 152-164. (Pubitemid 43261762)
4. Stupp R, Reni M, Gatta G, Mazza E, Vecht C (2007) Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63: 72-80. (Pubitemid 46810281)
5. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507.
6. Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, et al. (1999) Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91: 1382-1390. (Pubitemid 29399996)
7. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, et al. (2003) Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22: 2361-2373. (Pubitemid 36566791)
8. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453. (Pubitemid 47339290)
9. Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159: 779-786. (Pubitemid 32847166)
10. Prayson RA, Agamanolis DP, Cohen ML, Estes ML, Kleinschmidt-DeMasters BK, et al. (2000) Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. J NeurolSci 175: 33-39. (Pubitemid 30227481)
11. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79: 1381-1393. (Pubitemid 27143246)
12. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, et al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814-5819. (Pubitemid 40559642)
13. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, et al. (2005) Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 24: 7073-7083. (Pubitemid 41573636)
14. Bozinov O, Kohler S, Samans B, Benes L, Miller D, et al. (2008) Candidate genes for the progression of malignant gliomas identified by microarray analysis. Neurosurg Rev 31: 83-89. (Pubitemid 350165337)
15. Tso CL, Freije WA, Day A, Chen Z, Merriman B, et al. (2006) Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 66: 159-167. (Pubitemid 43166021)
16. Reddy SP, Britto R, Vinnakota K, Aparna H, Sreepathi HK, et al. (2008) Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Clin Cancer Res 14: 2978-2987.
17. Rao SA, Santosh V, Somasundaram K (2010) Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 23: 1404-1417.
18. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173. (Pubitemid 43357943)
19. Petalidis LP, Oulas A, Backlund M, Wayland MT, Liu L, et al. (2008) Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther 7: 1013-1024.
20. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572. (Pubitemid 34526173)
21. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121. (Pubitemid 32397092)
22. The Network TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
23. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, et al. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503-6510. (Pubitemid 39297907)
24. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, et al. (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329. (Pubitemid 11194457)
25. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018.
26. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, et al. (2003) Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163: 1033-1043. (Pubitemid 37040139)
27. Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, et al. (2003) Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63: 6613-6625. (Pubitemid 37322939)
28. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, et al. (2003) Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22: 4918-4923. (Pubitemid 36981282)
29. Dreyfuss JM, Johnson MD, Park PJ (2009) Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 8: 71.
30. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, et al. (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602-1607. (Pubitemid 36373650)
31. Yu Y, Jiang X, Schoch BS, Carroll RS, Black PM, et al. (2007) Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res 67: 130-138. (Pubitemid 46142768)
32. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, et al. (2005) YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 11: 3326-3334. (Pubitemid 40627883)
33. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, et al. (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12: 5698-5704. (Pubitemid 44629598)
34. Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, et al. (2011) Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 286: 15332-15343.
35. Ruano Y, Mollejo M, Ribalta T, Fiano C, Camacho FI, et al. (2006) Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol Cancer 5: 39.
36. Engel S, Isenmann S, Stander M, Rieger J, Bahr M, et al. (1999) Inhibition of experimental rat glioma growth by decorin gene transfer is associated with decreased microglial infiltration. J Neuroimmunol 99: 13-18. (Pubitemid 29488564)
37. Biglari A, Bataille D, Naumann U, Weller M, Zirger J, et al. (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 11: 721-732. (Pubitemid 39488470)
38. Stander M, Naumann U, Wick W, Weller M (1999) Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res 296: 221-227. (Pubitemid 29219174)
39. Santosh V, Arivazhagan A, Sreekanthreddy P, Srinivasan H, Thota B, et al. (2010) Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev 19: 1399-1408.
40. Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN (2004) Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84: 941-951. (Pubitemid 39025029)
41. Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, et al. (2001) In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 142: 1652-1658. (Pubitemid 32299696)
42. Khazenzon NM, Ljubimov AV, Lakhter AJ, Fujita M, Fujiwara H, et al. (2003) Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Mol Cancer Ther 2: 985-994.
43. Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, et al. (2008) PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer BiolTher 7: 663-668.
44. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, et al. (2010) Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 19: 1409-1422.
45. Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R (2006) Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep 15: 1569-1574.
46. Arivazhagan A, Kumar DM, Sagar V, Patric IR, Sridevi S, et al. (2012) Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor. J Neurooncol 107: 289-297.
47. Kahlert UD, Nikkhah G, Maciaczyk J (2012) Epithelial-to-mesenchymal(- like) transition as a relevant molecular event in malignant gliomas. Cancer Lett 331: 131-138.
48. Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, et al. (2010) TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer 9: 194.
49. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, et al. (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26: 756-784.